Pemetrexed in advanced non-small cell lung cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Global statistics cancer, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Ries LAG, Eisner MP, Kosary CL, editors, SEER Cancer Statistics Review, 1975–2001. Bethesda, MD: National Cancer Institute, 2004. Available from: http://seer.cancer.gov/csr/1975_2001/
   Google Scholar
• Sant M, Aareleid T, Berrino F. EUROCARE-3: survival of cancer patients diagnosed 1990–94′results and commentary. Ann Oncol 2003;14(Suppl 5):v61-v118
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-44
   PubMed Web of Science ®Google Scholar
• Breathnach OS, Freidlin B, Conley B, Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 2001;19:1734-42
   PubMed Web of Science ®Google Scholar
• Maione P, Rossi A, Bareschino MA, Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010. [Epub ahead of print]
   Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations [abstract LBA13]. 35 ESMO congress Milan; 8 – 12 October 2010
   Google Scholar
• Shih C, Chen VJ, Gossetti LS, LY231514, a pirrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997;57:1116-23
   PubMed Web of Science ®Google Scholar
• Schultz RM, Chen VJ, Bewley JR, Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26(Suppl 6):68-73
   PubMed Web of Science ®Google Scholar
• Ceppi P, Volante M, Saviozzi S, Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthetase. Cancer 2006;107:1589-96
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Monica V, Ceppi P, Baseline thymidylate synthetase expression according to histological subtypes of nonsmall cell lung cancer [abstract 7521]. J Clin Oncol 2009;27(15S):387s
   Google Scholar
• Niyikiza C, Baker SD, Seitz DE, Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes R, Flotten O, Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Rossi A, Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early-second line? Oncologist 2009;14:137-47
   PubMed Web of Science ®Google Scholar
• Grossi F, Aita M, Follador A, Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-64
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009;374:1432-40
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Peterson P, Park K, Fossella F, Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract P2-328]. J Thorac Oncol 2007;2(Suppl 4):S851
   Google Scholar
• Weiss GJ, Langer C, Rosell R, Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-11
   PubMed Web of Science ®Google Scholar